In the first article, by using ChIP assay, the authors show that p65 subunit of NF-κB following TRAIL treatment binds to the Mcl-1 promoter, which suggested that TRAIL induced expression of Mcl-1 through activation of NF-κB in HCT-116 colon carcinoma cells [17]. The gene discussed is MCL1; the disease is colon carcinoma.